| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.7K | 14.0% | 22.5% |
| Total Income | 1.8K | 11.9% | 21.9% |
| Expenditure | 1.4K | 6.6% | 20.0% |
| PBT | 362.13 | 27.6% | 21.0% |
| Net Profit | 261.48 | 42.4% | 27.7% |
| OPM | 24.21% | 3.10pp | 15.42pp |
| NPM | 14.87% | 3.18pp | 0.68pp |
| EPS | 15.87 | 42.3% | 27.8% |
Gland Pharma Posts Strong Q3 FY26 Results with 22% YoY Growth in Revenue and 37% adj. PAT Growth
28 Jan 2026 · 28 Jan, 5:33 pm
Summary
Gland Pharma Limited, a generic injectable-focused pharmaceutical company, announced its financial results for the third quarter ended December 31, 2025. The company reported a 22% year-on-year growth in revenue and a 37% growth in adjusted Profit After Tax (PAT). The strong performance was driven by robust year-on-year revenue growth in key markets like the US and Europe, and steady improvement in margins.
Key Highlights
- 1
Quarterly revenue increased by 22% year-on-year
- 2
Nine monthly revenues increased by 12%
- 3
Quarterly adj. EBITDA increased by 25% year-on-year; Nine monthly adj. EBITDA increased by 26%
- 4
Quarterly adj. PBT increased by 29% year-on-year; Nine monthly adj. PBT increased by 27%
- 5
Quarterly adj. PAT increased by 37% year-on-year; Nine monthly adj. PAT increased by 33%
Management Comments
Mr. Srinivas Sadu
Executive Chairman of Gland Pharma
Our strong Q3 FY26 performance, driven by robust year-on-year revenue growth of 22% and healthy adj. EBITDA margin of 26%, reflects the disciplined execution across our businesses. We remain confident in sustaining this momentum as new product launches, CDMO contract ramp-ups, and operational efficiencies continue to strengthen our trajectory.
Mr. Shyamakant Giri
Chief Executive Officer of Gland Pharma
Performance of Q3 FY26 was a clear reflection of consistent execution, with double-digit growth across key markets, of US and Europe, and steady improvement in margins. Cenexi’s breakeven and strong revenue traction in the base business were key contributors to our consolidated performance this quarter.
Informational and educational content only. Not investment advice.